These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 33639194)
21. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD. Ezhilarasan D Metabolism; 2024 Jun; 155():155912. PubMed ID: 38609038 [TBL] [Abstract][Full Text] [Related]
22. Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α. Liu T; Luo X; Li ZH; Wu JC; Luo SZ; Xu MY World J Gastroenterol; 2019 Sep; 25(36):5451-5468. PubMed ID: 31576092 [TBL] [Abstract][Full Text] [Related]
23. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats. Ge CX; Yu R; Xu MX; Li PQ; Fan CY; Li JM; Kong LD Eur J Pharmacol; 2016 Jan; 770():154-64. PubMed ID: 26593707 [TBL] [Abstract][Full Text] [Related]
24. Systems pharmacology-based exploration reveals mechanisms of anti-steatotic effects of Jiang Zhi Granule on non-alcoholic fatty liver disease. Zheng Y; Wang M; Zheng P; Tang X; Ji G Sci Rep; 2018 Sep; 8(1):13681. PubMed ID: 30209324 [TBL] [Abstract][Full Text] [Related]
25. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice. Inamdar S; Joshi A; Malik S; Boppana R; Ghaskadbi S Biochem Biophys Res Commun; 2019 Oct; 519(1):106-112. PubMed ID: 31472955 [TBL] [Abstract][Full Text] [Related]
26. Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice. Li S; Qian Y; Xie R; Li Y; Jia Z; Zhang Z; Huang R; Tuo L; Quan Y; Yu Z; Liu J; Xiang M J Ethnopharmacol; 2019 Oct; 242():112029. PubMed ID: 31216433 [TBL] [Abstract][Full Text] [Related]
27. Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. Zhang S; Wong YT; Tang KY; Kwan HY; Su T Front Endocrinol (Lausanne); 2020; 11():572729. PubMed ID: 33101207 [TBL] [Abstract][Full Text] [Related]
28. Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD). Chen Q; Wang T; Li J; Wang S; Qiu F; Yu H; Zhang Y; Wang T Nutrients; 2017 Jan; 9(2):. PubMed ID: 28146130 [TBL] [Abstract][Full Text] [Related]
29. PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. Chen H; Tan H; Wan J; Zeng Y; Wang J; Wang H; Lu X Pharmacol Ther; 2023 May; 245():108391. PubMed ID: 36963510 [TBL] [Abstract][Full Text] [Related]
30. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies. Ding X; He X; Tang B; Lan T Chin Med; 2024 Feb; 19(1):21. PubMed ID: 38310315 [TBL] [Abstract][Full Text] [Related]
31. [Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease]. Pan YT; Xu FY; Yu XZ; Shang WB Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(6):1109-1112. PubMed ID: 29027424 [TBL] [Abstract][Full Text] [Related]
32. Protective Effect and Mechanism of Plant-Based Monoterpenoids in Non-alcoholic Fatty Liver Diseases. Zhang W; Lin H; Cheng W; Huang Z; Zhang W J Agric Food Chem; 2022 Apr; 70(16):4839-4859. PubMed ID: 35436113 [TBL] [Abstract][Full Text] [Related]
33. Asiatic acid from Potentilla chinensis alleviates non-alcoholic fatty liver by regulating endoplasmic reticulum stress and lipid metabolism. Wang D; Lao L; Pang X; Qiao Q; Pang L; Feng Z; Bai F; Sun X; Lin X; Wei J Int Immunopharmacol; 2018 Dec; 65():256-267. PubMed ID: 30340105 [TBL] [Abstract][Full Text] [Related]
34. Carnosic acid protects mice from high-fat diet-induced NAFLD by regulating MARCKS. Song HM; Li X; Liu YY; Lu WP; Cui ZH; Zhou L; Yao D; Zhang HM Int J Mol Med; 2018 Jul; 42(1):193-207. PubMed ID: 29620148 [TBL] [Abstract][Full Text] [Related]
35. 2,3,5,4'-tetrahydroxystilbence-2-O-β-D-glucoside attenuates hepatic steatosis via IKKβ/NF-κB and Keap1-Nrf2 pathways in larval zebrafish. Wang C; Hu NH; Yu LY; Gong LH; Dai XY; Peng C; Li YX Biomed Pharmacother; 2020 Jul; 127():110138. PubMed ID: 32387861 [TBL] [Abstract][Full Text] [Related]
36. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells. Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174 [TBL] [Abstract][Full Text] [Related]
37. Herbal medicines and nonalcoholic fatty liver disease. Yao H; Qiao YJ; Zhao YL; Tao XF; Xu LN; Yin LH; Qi Y; Peng JY World J Gastroenterol; 2016 Aug; 22(30):6890-905. PubMed ID: 27570425 [TBL] [Abstract][Full Text] [Related]
38. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review. Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553 [TBL] [Abstract][Full Text] [Related]
39. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats. Deng Y; Pan M; Nie H; Zheng C; Tang K; Zhang Y; Yang Q Molecules; 2019 Oct; 24(21):. PubMed ID: 31683679 [TBL] [Abstract][Full Text] [Related]